FDA Finalizes Guidance Supporting Superiority Trials for ABS Drugs

Washington Drug Letter
Sponsors of clinical studies for antimicrobial drugs to treat acute bacterial sinusitis (ABS) should use superiority trials and demonstrate that the candidate affects the clinical course of the disease, according to finalized FDA guidance on the topic.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00